Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Calm Down

<< Previous

Bullboard Posts

Next >>

Comment by SeeDonRunon Sep 17, 2021 11:23am

92 Views

Post# 33877434

RE:RE:RE:RE:RE:Calm Down

Dude51 wrote: Sorry Amaze but I have no desire to go back to Dipshit Drew's site. So are you telling me only clas investors can sign up for CI site. That's wow. Kiss my ASSS DREW.

Normally I like your posts Dude but n this case, given your own history of berating posters like Raiders and Scotty for posting and having no shares it seems you are being quite hypocritical as you really have no business being here either.

You left gracefully and I aplauded that, this fixation with a board where you have no shares in sadly makes you a troll.

<< Previous

Bullboard Posts

Next >>

StockTalk | Gold Report: Government risk, green flags and a tax benefit